This is an oral combo of two drugs (one targeting GLP-1 receptors, the other amylin receptors). NOVOB +4%
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE
November 25, 2025 at 11:28 AM
This is an oral combo of two drugs (one targeting GLP-1 receptors, the other amylin receptors). NOVOB +4%
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE
*NOVO PHASE 2 WITH AMYCRETIN REPORTS `SIGNIFICANT' WEIGHT LOSS
*NOVO'S AMYCRETIN SHOWED WEIGHT LOSS OF UP TO 14.5% AT 36 WEEKS
*NOVO: AMYCRETIN APPEARED TO HAVE SAFE, WELL-TOLERATED PROFILE
FulcrumSec dropped the first part of the Novo Nordisk data, which includes "41,144 proprietary drug compounds with structures" and "the exact manufacturing recipe for Amycretin, the drug that added $80 billion to Novo’s market cap"
Intellectual Property (IP) is theft, but medical IP is murder.
Intellectual Property (IP) is theft, but medical IP is murder.
June 16, 2026 at 5:48 PM
FulcrumSec dropped the first part of the Novo Nordisk data, which includes "41,144 proprietary drug compounds with structures" and "the exact manufacturing recipe for Amycretin, the drug that added $80 billion to Novo’s market cap"
Intellectual Property (IP) is theft, but medical IP is murder.
Intellectual Property (IP) is theft, but medical IP is murder.
"the exact manufacturing recipe for Amycretin" damn that's so crazy that you leaked that, anyways this is united states patent US20230331803A1, granted to Novo Nordisk & published 6 august 2024, page 207 patents.google.com/patent/US202...
June 23, 2026 at 2:56 PM
"the exact manufacturing recipe for Amycretin" damn that's so crazy that you leaked that, anyways this is united states patent US20230331803A1, granted to Novo Nordisk & published 6 august 2024, page 207 patents.google.com/patent/US202...
The GLP-1 drugs (Ozempic and descendants) were just the beginning of a new gut hormone era in medicine
Here's Amycretin (oral and injectable), a dual agonist (GLP-1 and Amylin)
@thelancet.com
thelancet.com/journals/lan...
Here's Amycretin (oral and injectable), a dual agonist (GLP-1 and Amylin)
@thelancet.com
thelancet.com/journals/lan...
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60
mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists.
Although a high frequency of gastr...
thelancet.com
June 22, 2025 at 5:49 PM
The GLP-1 drugs (Ozempic and descendants) were just the beginning of a new gut hormone era in medicine
Here's Amycretin (oral and injectable), a dual agonist (GLP-1 and Amylin)
@thelancet.com
thelancet.com/journals/lan...
Here's Amycretin (oral and injectable), a dual agonist (GLP-1 and Amylin)
@thelancet.com
thelancet.com/journals/lan...
Amycretin vs big players 🥊🔥
🆚 Zepbound −22.5% (72w)
🆚 Wegovy −15% (68w)
🐂 Novo’s amycretin hits −23.2% in just 36w.
No plateau. Dual GLP-1/amylin agonism raising the stakes! 🚀
#NovoNordisk #Amycretin #Zepbound #Wegovy #ObesityStocks #NordicStocks
🆚 Zepbound −22.5% (72w)
🆚 Wegovy −15% (68w)
🐂 Novo’s amycretin hits −23.2% in just 36w.
No plateau. Dual GLP-1/amylin agonism raising the stakes! 🚀
#NovoNordisk #Amycretin #Zepbound #Wegovy #ObesityStocks #NordicStocks
June 21, 2025 at 9:26 AM
Amycretin vs big players 🥊🔥
🆚 Zepbound −22.5% (72w)
🆚 Wegovy −15% (68w)
🐂 Novo’s amycretin hits −23.2% in just 36w.
No plateau. Dual GLP-1/amylin agonism raising the stakes! 🚀
#NovoNordisk #Amycretin #Zepbound #Wegovy #ObesityStocks #NordicStocks
🆚 Zepbound −22.5% (72w)
🆚 Wegovy −15% (68w)
🐂 Novo’s amycretin hits −23.2% in just 36w.
No plateau. Dual GLP-1/amylin agonism raising the stakes! 🚀
#NovoNordisk #Amycretin #Zepbound #Wegovy #ObesityStocks #NordicStocks
August 6, 2025 at 10:33 AM
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
www.cnbc.com
January 24, 2025 at 12:39 PM
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Amycretin is in Phase I clinical trials. It’s not going to be on the market for 6-7 years assuming it makes it through trials. How did it add $80 B to Novo’s market cap?
FulcrumSec dropped the first part of the Novo Nordisk data, which includes "41,144 proprietary drug compounds with structures" and "the exact manufacturing recipe for Amycretin, the drug that added $80 billion to Novo’s market cap"
Intellectual Property (IP) is theft, but medical IP is murder.
Intellectual Property (IP) is theft, but medical IP is murder.
June 23, 2026 at 10:53 AM
Amycretin is in Phase I clinical trials. It’s not going to be on the market for 6-7 years assuming it makes it through trials. How did it add $80 B to Novo’s market cap?
Novo Nordisk’s amycretin 🐂💉 dropped impressive data at ADA 2025:
-24% weight loss at 36 wks (60 mg) vs placebo −1%.
Lower doses also strong:
20 mg −22%
5 mg −16%
1.25 mg −10%
No plateau yet; Phase 3 ahead! 🔥
#NovoNordisk #ADA2025 #Amycretin
-24% weight loss at 36 wks (60 mg) vs placebo −1%.
Lower doses also strong:
20 mg −22%
5 mg −16%
1.25 mg −10%
No plateau yet; Phase 3 ahead! 🔥
#NovoNordisk #ADA2025 #Amycretin
June 21, 2025 at 9:26 AM
Novo Nordisk’s amycretin 🐂💉 dropped impressive data at ADA 2025:
-24% weight loss at 36 wks (60 mg) vs placebo −1%.
Lower doses also strong:
20 mg −22%
5 mg −16%
1.25 mg −10%
No plateau yet; Phase 3 ahead! 🔥
#NovoNordisk #ADA2025 #Amycretin
-24% weight loss at 36 wks (60 mg) vs placebo −1%.
Lower doses also strong:
20 mg −22%
5 mg −16%
1.25 mg −10%
No plateau yet; Phase 3 ahead! 🔥
#NovoNordisk #ADA2025 #Amycretin
Amycretin, a novel weight management medication, showed promise in two recent early-phase clinical trials.
Find these trials & more in our latest issue: tinyurl.com/4me399k5
Find these trials & more in our latest issue: tinyurl.com/4me399k5
July 11, 2025 at 10:32 AM
Amycretin, a novel weight management medication, showed promise in two recent early-phase clinical trials.
Find these trials & more in our latest issue: tinyurl.com/4me399k5
Find these trials & more in our latest issue: tinyurl.com/4me399k5
On en a tous au moins un.
April 13, 2026 at 3:58 PM
On en a tous au moins un.
Novo Nordisk shares jump on fresh trial results
https://www.ft.com/content/986f61c8-d569-4d11-94ef-01a2f16a6865
https://www.ft.com/content/986f61c8-d569-4d11-94ef-01a2f16a6865
Novo Nordisk shares jump on fresh trial results
People treated with amycretin lost up to 22 per cent of their body weight after 36 weeks
www.ft.com
January 24, 2025 at 11:28 AM
Novo Nordisk shares jump on fresh trial results
https://www.ft.com/content/986f61c8-d569-4d11-94ef-01a2f16a6865
https://www.ft.com/content/986f61c8-d569-4d11-94ef-01a2f16a6865
Novo Nordisk stiger ~10% i dag pga. nye, gode resultater for amycretin.
Aktien er nu ~15% højere end bunden. Men der er stadig langt op til toppen fra i sommer. #dkøko
Aktien er nu ~15% højere end bunden. Men der er stadig langt op til toppen fra i sommer. #dkøko
January 24, 2025 at 11:08 AM
Novo Nordisk stiger ~10% i dag pga. nye, gode resultater for amycretin.
Aktien er nu ~15% højere end bunden. Men der er stadig langt op til toppen fra i sommer. #dkøko
Aktien er nu ~15% højere end bunden. Men der er stadig langt op til toppen fra i sommer. #dkøko
Amycretin looks way more more exciting than Cagrisema?
www.thelancet.com/journals/lan...
@littlebiggloms.bsky.social
www.thelancet.com/journals/lan...
@littlebiggloms.bsky.social
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60
mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists.
Although a high frequency of gastr...
www.thelancet.com
June 23, 2025 at 12:56 PM
Amycretin looks way more more exciting than Cagrisema?
www.thelancet.com/journals/lan...
@littlebiggloms.bsky.social
www.thelancet.com/journals/lan...
@littlebiggloms.bsky.social
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions. www.wsj.com/health/pharm...
Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial
www.wsj.com
November 25, 2025 at 12:08 PM
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions. www.wsj.com/health/pharm...
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year - www.reuters.com/business/hea... #$NOVO-B.CO #$NVO.NY #$NVO #Amycretin
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.
www.reuters.com
June 12, 2025 at 6:14 PM
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year - www.reuters.com/business/hea... #$NOVO-B.CO #$NVO.NY #$NVO #Amycretin
Novo Nordisk’s amycretin achieved 22% weight loss in an early obesity trial, the company said Friday.
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Novo Nordisk’s amycretin prompts 22% weight loss in early obesity trial
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday.
endpts.com
January 24, 2025 at 4:06 PM
Novo Nordisk’s amycretin achieved 22% weight loss in an early obesity trial, the company said Friday.
endpts.com/novo-nordisk...
endpts.com/novo-nordisk...
Novo Nordisk's experimental drug results in up to 24% weight loss reut.rs/464Pb8o
Novo Nordisk's experimental drug results in up to 24% weight loss
Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year.
reut.rs
June 20, 2025 at 11:40 PM
Novo Nordisk's experimental drug results in up to 24% weight loss reut.rs/464Pb8o
Yeni zayıflama ilacı erken denemelerde hem kan şekerini hem de iştahı hedef alıyor.
Amikretin adlı yeni bir ilaç, iki erken faz klinik çalışmasında kilo kaybına katkıda bulunabileceğini göstermiş.
Amikretin adlı yeni bir ilaç, iki erken faz klinik çalışmasında kilo kaybına katkıda bulunabileceğini göstermiş.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled...
In people with overweight or obesity, amycretin appeared safe and tolerable. Results
from this first-in-human, phase 1 study support further investigation of the weight
loss properties of amycretin.
www.thelancet.com
June 23, 2025 at 2:49 PM
Yeni zayıflama ilacı erken denemelerde hem kan şekerini hem de iştahı hedef alıyor.
Amikretin adlı yeni bir ilaç, iki erken faz klinik çalışmasında kilo kaybına katkıda bulunabileceğini göstermiş.
Amikretin adlı yeni bir ilaç, iki erken faz klinik çalışmasında kilo kaybına katkıda bulunabileceğini göstermiş.
$NVO Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks)
www.globenewswire.com/news-release...
Estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks)
www.globenewswire.com/news-release...
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1...
www.globenewswire.com
January 24, 2025 at 11:36 AM
$NVO Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks)
www.globenewswire.com/news-release...
Estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks)
www.globenewswire.com/news-release...
Initial trials found patients lost 13% of their bodyweight after 12 weeks of taking daily tablets containing amycretin, potentially easing the burden on the NHS ⬇️
New weight-loss drug is ‘better than Wegovy’ — and comes in a pill
www.thetimes.com
June 21, 2025 at 7:01 AM
Initial trials found patients lost 13% of their bodyweight after 12 weeks of taking daily tablets containing amycretin, potentially easing the burden on the NHS ⬇️
Amycretin: “New kid on the block”❓
🔹 Phase 1b/2a trial shows amycretin, a dual GLP-1/amylin receptor agonist
⤵️ body weight by up to 22% over 36 weeks.
🔸 Safety profile consistent with incretin therapies, with mild GI side effects.
❗️A promising therapy for #obesity & #T2D.
🔗 ggdocs.co/qjg1lw
🔹 Phase 1b/2a trial shows amycretin, a dual GLP-1/amylin receptor agonist
⤵️ body weight by up to 22% over 36 weeks.
🔸 Safety profile consistent with incretin therapies, with mild GI side effects.
❗️A promising therapy for #obesity & #T2D.
🔗 ggdocs.co/qjg1lw
News Details
ggdocs.co
January 24, 2025 at 11:36 AM
Amycretin: “New kid on the block”❓
🔹 Phase 1b/2a trial shows amycretin, a dual GLP-1/amylin receptor agonist
⤵️ body weight by up to 22% over 36 weeks.
🔸 Safety profile consistent with incretin therapies, with mild GI side effects.
❗️A promising therapy for #obesity & #T2D.
🔗 ggdocs.co/qjg1lw
🔹 Phase 1b/2a trial shows amycretin, a dual GLP-1/amylin receptor agonist
⤵️ body weight by up to 22% over 36 weeks.
🔸 Safety profile consistent with incretin therapies, with mild GI side effects.
❗️A promising therapy for #obesity & #T2D.
🔗 ggdocs.co/qjg1lw
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year Q12026 www.reuters.com/business/hea...
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.
www.reuters.com
June 12, 2025 at 7:09 PM
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year Q12026 www.reuters.com/business/hea...
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...
November 25, 2025 at 11:40 AM
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...